Ra Pharmaceuticals clinical trials

Acquired by UCB S.A., Apr 2, 2020 · source ↗

The registry lists 6 studies whose lead sponsor is Ra Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 16, 2025.

Before and after it joined UCB S.A.

First submitted before Ra Pharmaceuticals became part of UCB S.A.: 6
First submitted after Ra Pharmaceuticals became part of UCB S.A.: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 4
Terminated: 2

Phase

Phase 2: 5
Phase 3: 1

Where

United States: 5
Canada: 4
United Kingdom: 4
Germany: 3
New Zealand: 2
Hungary: 2

Registry sponsor names on this page

Ra Pharmaceuticals4 studies
Ra Pharmaceuticals, Inc.2 studies

Something wrong with this grouping? Tell us on the UCB S.A. page.

Studies

Recruiting first, then most recently updated. Showing 6 of 6. All UCB S.A. studies →

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia GravisCompletedNCT04115293Phase 3
Sponsor listed in the registry: Ra Pharmaceuticals, Inc. · First submitted before Ra Pharmaceuticals, Inc. became part of UCB S.A.
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical StudyTerminatedNCT03225287Phase 2
Sponsor listed in the registry: Ra Pharmaceuticals, Inc. · First submitted before Ra Pharmaceuticals, Inc. became part of UCB S.A.
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH PatientsCompletedNCT03078582Phase 2
Sponsor listed in the registry: Ra Pharmaceuticals · First submitted before Ra Pharmaceuticals became part of UCB S.A.
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia GravisCompletedNCT03315130Phase 2
Sponsor listed in the registry: Ra Pharmaceuticals · First submitted before Ra Pharmaceuticals became part of UCB S.A.
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing MyopathyTerminatedNCT04025632Phase 2
Sponsor listed in the registry: Ra Pharmaceuticals · First submitted before Ra Pharmaceuticals became part of UCB S.A.
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to EculizumabCompletedNCT03030183Phase 2
Sponsor listed in the registry: Ra Pharmaceuticals · First submitted before Ra Pharmaceuticals became part of UCB S.A.